Replies to post #273899 on Avid Bioservices Inc (CDMO)

[stoxx]

Keep up good work , we are ready to skyrocket soon

[Couch]

Thanks for the heads up CJ - Things certainly are beginning to heat up via the PPHM/MSK collaboration!

SITC’16 Abstract Titles: MSKCC/Wolchok-Lab & PPHM, Nov9-13, Natl-HarborMD – Reg. Abstract Titles released today! Take a look at #1, the joint MSKCC/PPHM one! Its Senior author is Dr. Taha Merghoub (Wolchok Lab), who said this in the 5-29-15 PPHM/MSK Collab. Announcement PR (see below): "A key focus of the Wolchok Lab's research is studying novel immunotherapy combinations that work together to enable the immune system to recognize & destroy cancer. This collaboration will allow us to focus on the role & contribution of PS blockade therapy in determining which combination of the current and next generation of immune modulators is likely to increase the extent and amplitude of anti-tumor response. This important pre-clinical & translational work will potentially guide the design of the next generation of clinical studies with bavituximab."

[masshysteria]

Thanks for posting cj and much to be excited about in here.

As a reference point, likely known to many on this board. Dr. Wolchok is a direct and significant contributor for the development and commercialization of both Ipilimumab and Nivolumab. He and his lab were there with BMY early on from discovery, development and through market research and ultimately launch. He is one of the world's most renowned experts on Melanoma as a disease, and the mechanisms and pathways associated with it. To state the obvious - he is also still very closely tied with further development of the products and any potential combinations that may induce the next level of response beyond what PD1 and CTLA4 can achieve on their own.

He was involved in study 1 and is also a contributing author. His work is changing the course of disease in humanity and he will be credited with delivering tremendous benefits to Oncology and patients as more Melanoma patients get treated with Nivolumab and survive what otherwise would be a death sentence.

And he's working with Bavituximab.
He's also working with mice. He always had. Even when developing Ipi and Nivo.

Should give anyone who is objective about the current state of affairs in Peregrine a pause and an appreciation of what the possibilities are. These people are drawn to high-potential and work with the largest of the largest in industry. They feel it is worth their time to spend it on Bavi-inclusive combinations.

I'm taking that as a positive sign.

Thanks much for sharing and best,

MH

[patientlywaiting]

Thanks to CJG we now have the much anticipated November Wolchok-Lab info we have all been waiting for. Although we don't know how many mice lived or died for the cause in Abstracts 1 & 2 we do know the fabulous results of number #3. I'm guess #'s 1 & 2 will show similar great results.

I guess no one needs to pump Wolchok November what we "might" be getting anymore.